Genitourinary cancers updates: highlights from ASCO 2023

Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qian, Sheffield, Hollie, Taasan, Sean M., Wang, Andrew Z., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662513/
https://www.ncbi.nlm.nih.gov/pubmed/37990343
http://dx.doi.org/10.1186/s13045-023-01511-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662513/
https://www.ncbi.nlm.nih.gov/pubmed/37990343
http://dx.doi.org/10.1186/s13045-023-01511-8

Ejemplares similares